HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*.

AbstractOBJECTIVES:
Infections in critically ill patients continue to impose diagnostic and therapeutic challenges. We seek to investigate the utility of proadrenomedullin and procalcitonin as diagnostic and prognostic biomarkers in febrile critically ill patients with cancer and compare their performance with that of C-reactive protein.
DESIGN:
Single-center prospective cohort study.
SETTING:
Tertiary care, academic, university hospital.
PATIENTS:
One hundred fourteen critically ill patients with cancer with fever.
INTERVENTIONS:
None.
MEASUREMENTS AND MAIN RESULTS:
Blood samples were withdrawn on the day of fever onset and 4 to 7 days thereafter, and the serum proadrenomedullin, procalcitonin, and C-reactive protein levels were measured using the Kryptor technology afterward. Of the 114 adult patients, 27 had bloodstream infections, 36 had localized infections, and the remaining had no infections. The area under the receiver operating characteristic curve for bloodstream infection diagnosis was significantly greater for proadrenomedullin (0.70; 95% CI, 0.59-0.82) and procalcitonin (0.71; 95% CI, 0.60-0.83) compared with C-reactive protein (0.53; 95% CI, 0.39-0.66) (p = 0.021 and p = 0.003, respectively). Receiver operating characteristic analysis also showed that proadrenomedullin (p = 0.005) and procalcitonin (p = 0.009) each had a better performance than C-reactive protein in predicting patients' mortality within 2 months after their fever onset. Regarding patients' response to antimicrobial therapy, proadrenomedullin, procalcitonin, and C-reactive protein levels all significantly decreased from baseline to follow-up in responders (p ≤ 0.002), whereas only proadrenomedullin level significantly increased in nonresponders (p < 0.0001). In patients with documented infections, proadrenomedullin (0.81; 95% CI, 0.71-0.92) and procalcitonin (0.73; 95% CI, 0.60-0.85) each had a greater area under the curve compared with C-reactive protein (0.59; 95% CI, 0.45-0.73) as for as predicting response (p = 0.004 and p = 0.043, respectively). However, for all febrile patients, proadrenomedullin had a significantly greater area under the curve for predicting favorable response than procalcitonin (p < 0.0001).
CONCLUSION:
In critically ill patients with cancer, proadrenomedullin and procalcitonin both have a promising role in predicting bloodstream infections in a manner more helpful than C-reactive protein. These two biomarkers were superior to C-reactive protein in the prognostic analysis of response to antimicrobial therapy for those patients with documented infections. However, proadrenomedullin was superior to procalcitonin in predicting response in all febrile patients and was unique in showing increased levels among nonresponders.
AuthorsLabib Debiane, Ray Y Hachem, Iba Al Wohoush, William Shomali, Ramez R Bahu, Ying Jiang, Anne-Marie Chaftari, Joseph Jabbour, Munirah Al Shuaibi, Alexander Hanania, S Egbert Pravinkumar, Philipp Schuetz, Issam Raad
JournalCritical care medicine (Crit Care Med) Vol. 42 Issue 12 Pg. 2500-7 (Dec 2014) ISSN: 1530-0293 [Electronic] United States
PMID25083975 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • CALCA protein, human
  • Protein Precursors
  • proadrenomedullin
  • Adrenomedullin
  • Calcitonin
  • C-Reactive Protein
  • Calcitonin Gene-Related Peptide
Topics
  • Academic Medical Centers
  • Adrenomedullin (blood)
  • Adult
  • Aged
  • Aged, 80 and over
  • Bacteremia (blood, epidemiology)
  • Biomarkers
  • C-Reactive Protein (analysis)
  • Calcitonin (blood)
  • Calcitonin Gene-Related Peptide
  • Critical Illness
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms (blood, epidemiology)
  • Prognosis
  • Prospective Studies
  • Protein Precursors (blood)
  • ROC Curve
  • Sepsis (blood, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: